Key result
CKD in severe aortic stenosis is linked to distinct multiomic profiles, highlighting VNN1 and A1AG1.
Why the study?
Chronic kidney disease accelerates calcific aortic stenosis progression and worsens clinical outcomes when both conditions coexist. Characterizing circulating molecular differences associated with CKD in patients with AS is needed to help define the molecular phenotype of this high-risk comorbidity.
Observational
This exploratory study identifies distinct plasma proteomic and metabolomic profiles—specifically verifying VNN1 and A1AG1—associated with chronic kidney disease in patients with severe aortic stenosis, highlighting pathways in inflammation, oxidative stress, and lipid metabolism.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for inflammatory pathways in aortic stenosis with chronic kidney disease; should not yet change practice.
Calcific aortic stenosis (AS) and chronic kidney disease (CKD) are progressive disorders associated with high morbidity and mortality. CKD accelerates AS progression and, when both conditions coexist, significantly worsens clinical outcomes. Therefore, characterizing circulating molecular differences associated with CKD in patients with AS may help define the molecular phenotype of this high-risk comorbidity. Plasma samples from patients with AS, with and without CKD, were analyzed through a multiomics approach using PASEF technology. Results were processed and analyzed using the bioinformatics tool Metascape to select two proteins with high potential as biomarkers: pantetheinase or vanin 1 (VNN1) and alpha 1 acid glycoprotein (A1AG1). These proteins were verified in an independent cohort of samples using immunodetection. Our findings show differences in the circulating proteomic and metabolomic profiles of patients with AS with and without CKD, suggesting that inflammation, oxidative stress and lipid metabolism are associated with CKD in this setting. These exploratory findings describe CKD-associated circulating proteomic and metabolomic differences in severe AS and provide hypotheses for validation in larger, appropriately controlled and longitudinal cohorts. These studies, which simultaneously examine multiple comorbidities, lay the groundwork for personalized medicine strategies, paving the way for more effective patient management.
No takes yet. Share an insight, caveat, or question.
Perales-Sánchez et al. (2026) conducted an observational in Severe calcific aortic stenosis with or without chronic kidney disease. Chronic kidney disease (CKD) vs. Severe aortic stenosis without chronic kidney disease was evaluated on Circulating proteomic and metabolomic profiles (including candidate biomarkers VNN1 and A1AG1). Chronic kidney disease in patients with severe aortic stenosis was associated with altered plasma proteomic and metabolomic profiles, identifying VNN1 and A1AG1 as verified candidate biomarkers.
Synapse has enriched 10 related papers. Consider them for comparative context: